Latest Information Update: 26 Jun 2002
At a glance
- Originator AtheroGenics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 26 Jun 2002 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 29 Mar 2001 No-Development-Reported for Solid tumours in USA (Unknown route)
- 10 Nov 1998 New profile